Simplify Logo

Full-Time

Director – Corporate Communications

Posted on 3/22/2024

Editas Medicine

Editas Medicine

201-500 employees

Develops CRISPR-based gene editing therapies

Hardware
Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Category
Content Strategy
Editing & Proofreading
Content & Writing
Copywriting
Required Skills
Communications
Requirements
  • 10+ years of public relations experience in pharmaceutical or biotech communications
  • Bachelor’s degree or higher
  • Strong ability to translate complex science into mainstream language
  • Ability to adapt to dynamic and evolving priorities
  • Experience in developing high-impact campaigns
  • Excellent interpersonal skills
  • Comfort and familiarity with a rapidly changing industry
  • Results-focused and collaborative professional
Responsibilities
  • Assist in developing and implementing Corporate Communications strategies aligned with corporate goals
  • Drive multiple ongoing projects and work with cross-functional teams
  • Develop and implement external communications strategy
  • Build social communications/media strategy and plan
  • Build strong relationships with external and internal stakeholders
  • Maintain comprehensive knowledge of company's research and development approaches
  • Collaborate with agency partners to grow corporate presence
  • Serve as a Company spokesperson to media

Editas Medicine is a leader in the biotechnology industry, focused on developing cutting-edge CRISPR gene editing technologies to create transformative medicines for serious diseases. This focus places the company at the forefront of genetic research and therapy development, providing a dynamic and pioneering environment for its employees. As a workplace, it promises a culture of constant learning and innovation, ideal for those passionate about advancing healthcare and contributing to vital medical breakthroughs.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

24%

2 year growth

13%
INACTIVE